JP2005511561A - 過活動膀胱の治療のための方法 - Google Patents
過活動膀胱の治療のための方法 Download PDFInfo
- Publication number
- JP2005511561A JP2005511561A JP2003539684A JP2003539684A JP2005511561A JP 2005511561 A JP2005511561 A JP 2005511561A JP 2003539684 A JP2003539684 A JP 2003539684A JP 2003539684 A JP2003539684 A JP 2003539684A JP 2005511561 A JP2005511561 A JP 2005511561A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- butyl
- dichlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- 206010020853 Hypertonic bladder Diseases 0.000 title claims description 9
- 208000009722 Overactive Urinary Bladder Diseases 0.000 title claims description 9
- 208000020629 overactive bladder Diseases 0.000 title claims description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 101
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 230000002265 prevention Effects 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 8
- -1 napsilate Chemical compound 0.000 claims description 20
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 10
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 10
- 206010046543 Urinary incontinence Diseases 0.000 claims description 8
- 239000007900 aqueous suspension Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000000443 aerosol Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 5
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- 230000001076 estrogenic effect Effects 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 claims description 3
- WBLYPMDGNCCKLM-HSZRJFAPSA-N n-[(2s)-2-(3,4-dichlorophenyl)-4-[4-(2-oxo-1,3-diazinan-1-yl)piperidin-1-yl]butyl]-n-ethylbenzamide Chemical compound C([C@H](CN(CC)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1N1CCCNC1=O WBLYPMDGNCCKLM-HSZRJFAPSA-N 0.000 claims description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 3
- 229960001860 salicylate Drugs 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- AYMWOFHCSHVAJI-HSZRJFAPSA-N n-[(2s)-2-(3,4-dichlorophenyl)-4-[4-(5,5-dimethyl-2-oxo-1,3-diazinan-1-yl)piperidin-1-yl]butyl]-n-methylbenzamide Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1N1CC(C)(C)CNC1=O AYMWOFHCSHVAJI-HSZRJFAPSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- SCMPVSAUZONHCN-JOCHJYFZSA-N n-[(2s)-2-(3,4-dichlorophenyl)-4-[4-(2-oxo-1,3-diazinan-1-yl)piperidin-1-yl]butyl]-n-methylbenzamide Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1N1CCCNC1=O SCMPVSAUZONHCN-JOCHJYFZSA-N 0.000 claims 1
- 229950006327 napsilate Drugs 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 102100037342 Substance-K receptor Human genes 0.000 abstract description 13
- 101000600912 Homo sapiens Substance-K receptor Proteins 0.000 abstract description 7
- 241000124008 Mammalia Species 0.000 abstract description 5
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 156
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- 239000000243 solution Substances 0.000 description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 14
- 239000003480 eluent Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000008602 contraction Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 206010021639 Incontinence Diseases 0.000 description 8
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000021 stimulant Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 210000003708 urethra Anatomy 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- YKQYXBIOTJSMDN-UHFFFAOYSA-N 5,5-dimethyl-1-piperidin-4-yl-1,3-diazinan-2-one Chemical compound C1C(C)(C)CNC(=O)N1C1CCNCC1 YKQYXBIOTJSMDN-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101000600903 Homo sapiens Substance-P receptor Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102100024304 Protachykinin-1 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- LWMHCPBJEGVKTA-MRXNPFEDSA-N n-[(2s)-2-(3,4-dichlorophenyl)-4-oxobutyl]-n-ethylbenzamide Chemical compound C1([C@H](CC=O)CN(CC)C(=O)C=2C=CC=CC=2)=CC=C(Cl)C(Cl)=C1 LWMHCPBJEGVKTA-MRXNPFEDSA-N 0.000 description 3
- YNZBAHMTKMMLCG-JOCHJYFZSA-N n-[(2s)-4-[4-(3-aminopropylamino)piperidin-1-yl]-2-(3,4-dichlorophenyl)butyl]-n-methylbenzamide Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN1CCC(NCCCN)CC1 YNZBAHMTKMMLCG-JOCHJYFZSA-N 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- UKVNVUSJWJGCNU-UHFFFAOYSA-N 1-ethyl-3-piperidin-4-yl-1,3-diazinan-2-one Chemical compound O=C1N(CC)CCCN1C1CCNCC1 UKVNVUSJWJGCNU-UHFFFAOYSA-N 0.000 description 2
- WQEZNOIZYDJGLE-UHFFFAOYSA-N 1-piperidin-4-yl-1,3-diazinan-2-one Chemical compound O=C1NCCCN1C1CCNCC1 WQEZNOIZYDJGLE-UHFFFAOYSA-N 0.000 description 2
- UIKCPFRRUOWQHT-UHFFFAOYSA-N 2,2,2-trifluoro-n-[3-[piperidin-4-yl-(2,2,2-trifluoroacetyl)amino]propyl]acetamide Chemical compound FC(F)(F)C(=O)NCCCN(C(=O)C(F)(F)F)C1CCNCC1 UIKCPFRRUOWQHT-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010043268 Tension Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000005068 bladder tissue Anatomy 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000451 chemical ionisation Methods 0.000 description 2
- 239000002027 dichloromethane extract Substances 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000010265 fast atom bombardment Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- VLQIYTMUXAIPJQ-CQSZACIVSA-N n-[(2s)-2-(3,4-dichlorophenyl)-4-hydroxybutyl]benzamide Chemical compound C([C@@H](CCO)C=1C=C(Cl)C(Cl)=CC=1)NC(=O)C1=CC=CC=C1 VLQIYTMUXAIPJQ-CQSZACIVSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- IXSRSYZHKFLVEK-GFCCVEGCSA-N tert-butyl n-[(2s)-2-(3,4-dichlorophenyl)-4-oxobutyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C[C@@H](CC=O)C1=CC=C(Cl)C(Cl)=C1 IXSRSYZHKFLVEK-GFCCVEGCSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- TXNNHWQFMLDTLO-SECBINFHSA-N (3s)-3-(3,4-dichlorophenyl)-4-(methylamino)butan-1-ol Chemical compound CNC[C@@H](CCO)C1=CC=C(Cl)C(Cl)=C1 TXNNHWQFMLDTLO-SECBINFHSA-N 0.000 description 1
- RZAUZYHHIDAIDR-MRXNPFEDSA-N 1-[1-[(3s)-3-(3,4-dichlorophenyl)-4-(methylamino)butyl]piperidin-4-yl]-1,3-diazinan-2-one Chemical compound C([C@H](CNC)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1N1CCCNC1=O RZAUZYHHIDAIDR-MRXNPFEDSA-N 0.000 description 1
- HKYDOZFIGQCQMS-UHFFFAOYSA-N 2,2,2-trifluoro-N-[3-[piperidin-1-yl-(2,2,2-trifluoroacetyl)amino]propyl]acetamide Chemical compound FC(C(=O)N(CCCNC(C(F)(F)F)=O)N1CCCCC1)(F)F HKYDOZFIGQCQMS-UHFFFAOYSA-N 0.000 description 1
- DDHUNHGZUHZNKB-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diamine Chemical compound NCC(C)(C)CN DDHUNHGZUHZNKB-UHFFFAOYSA-N 0.000 description 1
- GKTFLKJXZOYBRW-UHFFFAOYSA-N 2-ethylbenzamide Chemical compound CCC1=CC=CC=C1C(N)=O GKTFLKJXZOYBRW-UHFFFAOYSA-N 0.000 description 1
- YHLVEHXOBBYATA-UHFFFAOYSA-N 5,5-dimethyl-1,3-diazinan-2-one Chemical compound CC1(C)CNC(=O)NC1 YHLVEHXOBBYATA-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108010072901 Tachykinin Receptors Proteins 0.000 description 1
- 102000007124 Tachykinin Receptors Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108010036928 Thiorphan Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- AUVGEBAXLDBELX-HXUWFJFHSA-N [(3s)-4-benzamido-3-(3,4-dichlorophenyl)butyl] benzoate Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@@H](CNC(=O)C=1C=CC=CC=1)CCOC(=O)C1=CC=CC=C1 AUVGEBAXLDBELX-HXUWFJFHSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- VFFLTVRGXRGMBA-UHFFFAOYSA-N benzyl 4-(2-oxo-1,3-diazinan-1-yl)piperidine-1-carboxylate Chemical compound C1CC(N2C(NCCC2)=O)CCN1C(=O)OCC1=CC=CC=C1 VFFLTVRGXRGMBA-UHFFFAOYSA-N 0.000 description 1
- SRAHAKLADOCBPU-UHFFFAOYSA-N benzyl 4-(3-aminopropylamino)piperidine-1-carboxylate Chemical compound C1CC(NCCCN)CCN1C(=O)OCC1=CC=CC=C1 SRAHAKLADOCBPU-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960000855 flavoxate Drugs 0.000 description 1
- SPIUTQOUKAMGCX-UHFFFAOYSA-N flavoxate Chemical compound C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 SPIUTQOUKAMGCX-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- IIXYKSFDBKSCCT-GJICFQLNSA-N n-[(2s)-2-(3,4-dichlorophenyl)-4-[4-(2-sulfanylidene-1,3-diazinan-1-yl)piperidin-1-yl]butyl]-n-methylbenzamide;dihydrochloride Chemical compound Cl.Cl.C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1N1CCCNC1=S IIXYKSFDBKSCCT-GJICFQLNSA-N 0.000 description 1
- HXUYGJYFAHHPKD-MRXNPFEDSA-N n-[(2s)-2-(3,4-dichlorophenyl)-4-hydroxybutyl]-n-ethylbenzamide Chemical compound C1([C@H](CCO)CN(CC)C(=O)C=2C=CC=CC=2)=CC=C(Cl)C(Cl)=C1 HXUYGJYFAHHPKD-MRXNPFEDSA-N 0.000 description 1
- LEEARGALTPRPLU-OAHLLOKOSA-N n-[(2s)-2-(3,4-dichlorophenyl)-4-oxobutyl]-n-methylbenzamide Chemical compound C1([C@H](CC=O)CN(C)C(=O)C=2C=CC=CC=2)=CC=C(Cl)C(Cl)=C1 LEEARGALTPRPLU-OAHLLOKOSA-N 0.000 description 1
- VQERENHYMVOLOU-OAQYLSRUSA-N n-[(2s)-4-[tert-butyl(dimethyl)silyl]oxy-2-(3,4-dichlorophenyl)butyl]-n-ethylbenzamide Chemical compound C1([C@H](CCO[Si](C)(C)C(C)(C)C)CN(CC)C(=O)C=2C=CC=CC=2)=CC=C(Cl)C(Cl)=C1 VQERENHYMVOLOU-OAQYLSRUSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- LMAWOZXAUUOBPC-UHFFFAOYSA-N piperidine (2,2,2-trifluoroacetyl) 2,2,2-trifluoroacetate Chemical compound C1CCNCC1.FC(F)(F)C(=O)OC(=O)C(F)(F)F LMAWOZXAUUOBPC-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960003510 propiverine Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103668A SE0103668D0 (sv) | 2001-11-02 | 2001-11-02 | Method for the treatment of overactive blader |
| PCT/SE2002/001990 WO2003037341A1 (en) | 2001-11-02 | 2002-11-01 | Method for the treatment of overactive bladder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005511561A true JP2005511561A (ja) | 2005-04-28 |
| JP2005511561A5 JP2005511561A5 (enExample) | 2006-01-05 |
Family
ID=20285870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003539684A Pending JP2005511561A (ja) | 2001-11-02 | 2002-11-01 | 過活動膀胱の治療のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040248914A1 (enExample) |
| EP (1) | EP1450805A1 (enExample) |
| JP (1) | JP2005511561A (enExample) |
| KR (1) | KR20050042211A (enExample) |
| CN (1) | CN1622806A (enExample) |
| BR (1) | BR0213776A (enExample) |
| CA (1) | CA2465140A1 (enExample) |
| IL (1) | IL161599A0 (enExample) |
| MX (1) | MXPA04004071A (enExample) |
| NO (1) | NO20042139L (enExample) |
| SE (1) | SE0103668D0 (enExample) |
| WO (1) | WO2003037341A1 (enExample) |
| ZA (1) | ZA200403199B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006121389A1 (en) * | 2005-05-10 | 2006-11-16 | Astrazeneca Ab | Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity |
| TWI667034B (zh) * | 2016-09-21 | 2019-08-01 | 惠眾生技股份有限公司 | 關刀豆用於製備保護膀胱避免損傷藥劑之用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE300218B (enExample) * | 1960-11-08 | 1968-04-22 | Recip Ab | |
| US5382600A (en) * | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| GB8906166D0 (en) * | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| GB9310713D0 (en) * | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Aryl substituted heterocycles |
| GB9317104D0 (en) * | 1993-08-17 | 1993-09-29 | Zeneca Ltd | Therapeutic heterocycles |
| US6008223A (en) * | 1994-10-27 | 1999-12-28 | Zeneca Limited | Therapeutic compounds |
| GB9505084D0 (en) * | 1995-03-14 | 1995-05-03 | Pfizer Ltd | Benzamide derivative |
| GB9922519D0 (en) * | 1998-10-07 | 1999-11-24 | Zeneca Ltd | Compounds |
| GB9924141D0 (en) * | 1998-10-30 | 1999-12-15 | Zeneca Ltd | Treatment of gastric asthma |
| GB9826941D0 (en) * | 1998-12-09 | 1999-02-03 | Zeneca Pharmaceuticals | Compounds |
| GB0015246D0 (en) * | 2000-06-22 | 2000-08-16 | Astrazeneca Ab | Method for the treatment of urinary incontinence |
-
2001
- 2001-11-02 SE SE0103668A patent/SE0103668D0/xx unknown
-
2002
- 2002-11-01 WO PCT/SE2002/001990 patent/WO2003037341A1/en not_active Ceased
- 2002-11-01 KR KR1020047006519A patent/KR20050042211A/ko not_active Withdrawn
- 2002-11-01 JP JP2003539684A patent/JP2005511561A/ja active Pending
- 2002-11-01 IL IL16159902A patent/IL161599A0/xx unknown
- 2002-11-01 EP EP02783903A patent/EP1450805A1/en not_active Withdrawn
- 2002-11-01 US US10/494,387 patent/US20040248914A1/en not_active Abandoned
- 2002-11-01 BR BR0213776-3A patent/BR0213776A/pt not_active IP Right Cessation
- 2002-11-01 CA CA002465140A patent/CA2465140A1/en not_active Abandoned
- 2002-11-01 MX MXPA04004071A patent/MXPA04004071A/es unknown
- 2002-11-01 CN CNA028266005A patent/CN1622806A/zh active Pending
-
2004
- 2004-04-28 ZA ZA200403199A patent/ZA200403199B/en unknown
- 2004-05-25 NO NO20042139A patent/NO20042139L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1450805A1 (en) | 2004-09-01 |
| BR0213776A (pt) | 2004-11-09 |
| ZA200403199B (en) | 2005-02-09 |
| CN1622806A (zh) | 2005-06-01 |
| KR20050042211A (ko) | 2005-05-06 |
| US20040248914A1 (en) | 2004-12-09 |
| SE0103668D0 (sv) | 2001-11-02 |
| NO20042139L (no) | 2004-06-25 |
| CA2465140A1 (en) | 2003-05-08 |
| WO2003037341A1 (en) | 2003-05-08 |
| MXPA04004071A (es) | 2004-09-06 |
| IL161599A0 (en) | 2004-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2193557C2 (ru) | Бензоциклогептатиофеновые соединения, способы профилактики или лечения, фармацевтическая композиция | |
| JP3534765B2 (ja) | 喘息治療用のニューロキニン２受容体拮抗薬としての新規な４−ピペリジニル置換ラクタム | |
| EA009455B1 (ru) | Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами | |
| JPH07119213B2 (ja) | ムスカリンリセプターアンタゴニスト | |
| CZ114199A3 (cs) | N-Substituované azaheterocyklické sloučeniny | |
| US20080261976A1 (en) | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same | |
| JPH07145057A (ja) | 縮合ベンゼンオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤 | |
| US5508306A (en) | Aromatic amine derivatives | |
| WO1995007075A9 (en) | Novel aromatic amine derivatives | |
| TWI236469B (en) | Diamine compound with condensed-ring groups | |
| CA2770766C (en) | Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones | |
| US7368461B2 (en) | Compounds and method for the treatment of overactive bladder | |
| JP2001501937A (ja) | Ｎ―置換化アザ複素環式化合物 | |
| EP1307202B1 (en) | Method for the treatment of overactive bladder | |
| JP2005511561A (ja) | 過活動膀胱の治療のための方法 | |
| AU2002347708A1 (en) | Method for the treatment of overactive bladder | |
| TW201125860A (en) | Prodrugs of [4-[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof | |
| AU2002347709A1 (en) | Compounds and method for the treatment of overactive bladder | |
| WO1996031471A1 (en) | Novel method | |
| HK1076732A (en) | Method for the treatment of overactive bladder | |
| HK1075658A (en) | Compounds and method for the treatment of overactive bladder | |
| JPWO2001034569A1 (ja) | 膵炎治療剤 | |
| WO1996032370A1 (en) | 4-amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds | |
| WO1996031502A1 (en) | Novel heterocyclic compounds | |
| HK1038927A1 (en) | (1-Phenacy-3-phenyl-3-piperidylethyl) piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051012 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051012 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090721 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091215 |